Published on September 17, 2021
THURSDAY, September 12, 2021 (Reuters) — Britain’s state-run National Health Service will on Monday begin the world’s biggest trial of Grail Inc’s (GRAL.O) flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.
The Galleri test looks at the DNA in a patient’s blood to determine if any come from cancer cells. Earlier diagnosis of cancers leads to dramatically increased survival rates.
What every guy needs to know about prostate cancer
September 15, GQ
Biologists identify new targets for cancer vaccines
September 16, MIT News
Having a cousin or grandparent with colon cancer raises your risk
September 15, WebMD
Special enrollment for ACA health plans attracts nearly 3 million consumers
September 15, The Washington Post
The Prevent Cancer Foundation announces funding for five new cervical cancer prevention and early detection projects in low- or middle-income countries in support of the World Health Organization’s (WHO’s) call for the elimination of cervical cancer by 2030.
Cervical cancer is highly preventable and treatable when found early, yet women worldwide lack access to the prevention and screening tools necessary to protect them. The Foundation is proud to support these projects through its global grants program, which focuses on assessing innovative technologies and delivering services and/or education to improve or expand quality cancer screening or prevention.
Support more great work like this by donating today.